Editor’s Note: This article and information is credited to American Chemical Society (ACS).
Constant glucose monitoring and frequent insulin injections could someday be replaced with an “artificial pancreas” for people with Type 1 diabetes.
Constant glucose monitoring and frequent insulin injections could someday be replaced with an “artificial pancreas” for people with Type 1 diabetes.
Credit: ratmaner/iStock/Thinkstock
Living with Type 1 diabetes requires constant monitoring of blood sugar levels and injecting insulin daily. Now scientists are reporting in the ACS journal, “Industrial & Engineering Chemistry Research,” the development of an implantable “artificial pancreas” that continuously measures a person’s blood sugar or glucose level and can automatically release insulin as needed.
Type 1 diabetes, previously known as juvenile diabetes, affects about 1.25 million Americans. About 200,000 of them are under 20 years old. The condition arises when a person’s own immune system destroys the pancreas cells that make insulin, the hormone that converts blood sugar into energy.
To make up for this loss of insulin production, patients must take insulin daily. Current delivery methods involve multiple daily injections or insulin pump therapy, both requiring the user to actively track glucose and calculate the needed insulin dose. There is also a significant time lag between when a dose is needed and when it can take effect. Francis J. Doyle III and colleagues wanted to find a way to make monitoring and insulin delivery automatic and needle-free.
The researchers designed an algorithm that monitors blood sugar levels and computes an insulin dose that it delivers quickly and automatically when necessary. The algorithm is designed to work with implanted devices, specifically with an artificial pancreas, and would overcome the delays experienced with current devices. Computer testing of the algorithm simulated the rise and fall of glucose that would correspond to meals and an overnight period of sleep. The artificial pancreas maintained blood glucose within the target range nearly 80% of the time. The researchers say they will soon test the device in animals.
The authors acknowledge funding from the National Science Foundation and the National Institutes of Health.
ACS Industrial & Engineering Chemistry Research
pubs.acs.org
